{"title":"Early promising results with addition of an ICI and an anti-angiogenic to TACE","authors":"Diana Romero","doi":"10.1038/s41571-025-00990-7","DOIUrl":null,"url":null,"abstract":"<p>Transarterial chemoembolization (TACE) is the standard-of-care treatment for patients with intermediate-stage hepatocellular carcinoma (HCC) who are not candidates for resection, ablation or transplantation, although disease recurrence is common. Now, early data from two phase III trials demonstrate that the addition of both an immune-checkpoint inhibitor (ICI) and an anti-angiogenic agent to TACE improves patient outcomes.</p><p>Both trials involved patients with Barcelona Clinic Liver Cancer stage A–C non-metastatic HCC amenable to TACE. In LEAP-012, 480 patients were randomly allocated (1:1) to TACE (with a maximum of two treatments per tumour) and either pembrolizumab plus lenvatinib or double placebo. In EMERALD-1, 616 patients were randomly allocated (1:1:1) to TACE (1–4 procedures) and either durvalumab plus bevacizumab, durvalumab plus placebo or placebo alone. The primary end point of both trials was progression-free survival (PFS).</p>","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"114 1","pages":""},"PeriodicalIF":81.1000,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41571-025-00990-7","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Transarterial chemoembolization (TACE) is the standard-of-care treatment for patients with intermediate-stage hepatocellular carcinoma (HCC) who are not candidates for resection, ablation or transplantation, although disease recurrence is common. Now, early data from two phase III trials demonstrate that the addition of both an immune-checkpoint inhibitor (ICI) and an anti-angiogenic agent to TACE improves patient outcomes.
Both trials involved patients with Barcelona Clinic Liver Cancer stage A–C non-metastatic HCC amenable to TACE. In LEAP-012, 480 patients were randomly allocated (1:1) to TACE (with a maximum of two treatments per tumour) and either pembrolizumab plus lenvatinib or double placebo. In EMERALD-1, 616 patients were randomly allocated (1:1:1) to TACE (1–4 procedures) and either durvalumab plus bevacizumab, durvalumab plus placebo or placebo alone. The primary end point of both trials was progression-free survival (PFS).
期刊介绍：
Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
